I
n hospitals, nursing homes and home-care facilities the emergence and dissemination of antibiotic-resistant bacteria is causing increasing problems in wound care. Methicillinresistant Staphylococcus aureus (MRSA)is one of the most prevalent and recalcitrant pathogens compromising wound healing.I.3 Aside from the rnicroenvironmental problem, it is having a big impact on health-care costs.
Demand is therefore increasing for wound-care devices with antibacterial properties that will prevent re-infection during the healing process. Such products should be:
. Certifiedfor wound care . Biocompatible, standardised and sterile .Sui table for prolonged application .Appl icable for all of the stages of wound healing . Suitable for both acute and chronic wounds.
They must also support moist wound healing. Medical grade honeys have been found to satisfy these requirements, and the scope of their usage in wound care is increasing.4-7 If certified as a medical device,8 honey is safe to use and, as well as keeping the wound free from bacterial colonisation, may promote healing. Additional benefits include swift deodorisation of malodorous wounds and reduced pain at dressing changes.9.11
In this retrospective case series we report on seven consecutive patients with wounds chronically infected or colonised with MRSAthat were treated with Medihoney wound-care products (Medihoney [Europe] , Reading, UK).
The success achieved with this treatment, including on patients whom it is beyond the scope of this report to include, encouraged us to use these products more frequently and to initiate a multicentre clinical observational study with a database (Woundpecker) specifically developed for this task.
Method

Patients
Data were collected using a case report form from the files of patients: VOL 16, NO 8, SEPTEMBER 2007 . In whom MRSA colonisation/infection had been detected in a wound swab in the previous five years .Whose wounds had been treated with antibacterial medical honey by a wound-care specialist (GB). Patient 4 has been included in a previous report about the use of Medihoney products in severely immunocompromised children.11
Patient informed consent to use their data for scientific and educationa~purposes was obtained at the start of treatment, Ethical approval was not required as Medihoney products are licensed, CE-certificated medical products for wound care in Germany.
Wound treatment and data collection Medihoney Antibacterial Medical Honey was used to treat the wounds. In accordance with the internal wound-care standard for the use of Antibacterial Medical Honey, the dressings were changed daily by a professional wound-care nurse or a trained relative when patients were being cared for at home.
In most cases the honey was applied onto a calcium alginate dressing (Sorbalgon, Paul Hartmann AG, Heidenheim), which was then placed directly over the wound. In our experience this dressing keeps antibacterial honey in permanent contact with the wound surface. Fistulas were filled with medical honey, and a calcium alginate dressing was only applied if the outer diameter of the fistula was larger than lcm.
Wounds with apparent clinical signs of infection were pre-treated with an antiseptic (Octenidinehydrochloride, Octenisept, SchUlke &:Ma.yr,Nordersted) on the first day of treatment only. In some cases the attending physician also prescribed systemic antibiotics to patients with local or systemic signs of wound infection.
Wound swabs were investigated, following standard microbiological procedures,I2 at the Institute of Medical Microbiology, Immunology and Parasitology, University of Bonn.
Given the retrospective nature of this case series, the frequency of the microbiological investigations was not considered in the evaluation (okay? general, wound swabs were taken from inpatients at least once weekly; there were no recommendations for microbiological investigations in outpatients at the time of treatment.
Results
The clinical manifestations of the seven patients are summarised in Table 1 . In addition to the MRSA infection or colonisation of their wounds, all had significant comorbidities that affect wound healing. Six had surgical wounds.
Despite the use of topical antiseptics in some patients, and systemic administration of vancomycin in three, MRSAwound infections had persisted for up to five years (Table 1) .
Clinical outcomes achieved with the medical honey are summarised in Table 2 . Patient acceptance of wound treatment with honey was good. Its positive effect on wound cleansing and healing encouraged patient concordance. Patient 1 was unable to comply with basic principles of wound hygiene due to excessive alcohol abuse.
MRSA was eradicated in all wounds without the further use of topical antiseptics or systemic antibiotics. In five patients the exact time required to eradicate the bacteria could not be determined because wound swabs were not taken on a regular basis. However, swabs were taken on the days indicated in Table 2 Octenisept for 13 days for MRSA eradication. Following treatment with Medihoney, no bacteria were detected after two days.
None of the other patients experienced any pain related to the application of the medical honey, with the exception of patient 7 who discontinued the treatment because it resulted in severe pain that turned out to be opioid-resistant. The pain stopped soon after this.
All wounds healed after treatment with the medical honey. In patient 7 the medical honey evidently improved the wound's condition, and it healed after 102 further days of treatment with TenderWet (Hartmann) (outpatient basis).
Discussion
Although detailed data are not available on the detection of MRSA in wound-care settings in Germany, reports from other countries describe MRSA as a causative pathogen with an increased prevalence in skin and soft-tissue infections, adult and paediatric emergency patients, surgical wound infections13 and patients with chronic wounds.14.16 Antibiotic-resistant bacterial strains often thrive in wounds, with profound detrimental effects on healing.17,18 Medical honey exhibits its primary antibacterial effects by inducing autolytic debridement, supported by the action of its high osmolarity and low pH.4.7
When diluted, some honeys have additional antibacterial properties due to the action of the enzyme glucose oxidase and still unidentified active components that have exhibited a significant antibacterial effect in vitro when hydrogen peroxide production was chemically blocked. 6, 7, 19 The antibacterial effects of honey are not comparable to those of antiseptics, which achieve a 5 logreduction of bacterial counts within two minutes. Nevertheless, our data support the finding of other groups that medical honey efficiently controls co1-onisation and local infection.
Unfortunately, in contrast to current practice, wound swabs were not taken on a weekly basis. Thus, we can only speculate about the duration of infection in most of the wounds. This needs to be addressed in a prospective study.
Importantly, the use of medical honey has not been observed to foster bacterial resistance or to have any toxic effects20 after prolonged application.21 This is of particular relevance to paediatric patients, who may be more susceptible to systemic toxicity after resorption of compounds used in wound care.22,23
A practical challenge was application of the product to vertical wounds (such as leg ulcers or abdominal wounds) in ambulatory patients. Sustained contact was achieved by soaking the honey into a calcium alginate dressing, which was kept in place under a sterile gauze layer covered with a vapourpermeable transparent film.
Medihoney dressings still have to be changed daily as no other standard of treatment has been published. This may increase demand for staff resources and result in relatively high costs. Some wounds may have iittle or no exudate, in which case dressing changes on alternate days or even longer would be feasible, although prospective studies on this issue are lacking.
The lack of randomised controlled trials on the use of Medihoney in wound care is a major obstacle for practitioners, and necessitates consideration of more evidence-based treatments. With only a few exceptions, 21 Medihoney still remains a compassionate treatment approach for patients in whom other treatments have failed. As a minimal safety requirement, its use on complex wounds and in patients with severe pre-existing comorbidities should be supervised by a physician or a woundcare specialist.
Concordance can be a serious problem in patients with complex wounds, in particular in the homecare setting (see patient I, in whom non-concordance was associated with alcohol abuse).
Wound care in outpatients is still not standardised in Germany and even state-of-the-art woundcare interventions are not always paid for by insurance companies.
Pain occasionally occurs after administration of medical honey for reasons that are not yet fully understood. This may because the high sugar concentration draw fluids from the wound tissues and due to the low pH (approximately 4). The Medihoney wound gel preparation (Medihoney Wound Gel), which contains a wax ester and ethoxylated oil derived from organic plant sources, has solved the pain problem in some patients (unpublished observations) . Application of local anaesthetics such as lidocaine-prilocaine (EMLA, AstraZeneca) cream may be helpful but the side-effect of prolonged local vasoconstriction may outweigh the benefit in wounds where perfusion is impaired.
Conclusion
These results should encourage others to use CE certified antibacterial honey dressin,gs in wounds infected or colonised with MRSA. Nonetheless, prospective randomised studies are urgently needed to confirm the real benefit of this unconventional treatment approach. We recently developed a database (Woundpecker, Children's Hospital, University of Bonn, Germany) for the standardised collection of datasets on the clinical use of Medihoney products in wound care, with a view to fostering the collection of clinical evidence and to perform prospective comparative studies in the near future..
